Accelerated Approval Drug Promotions Run Risk Of Overstating Efficacy, Understating Safety

Skunk
By promoting data from a confirmatory trial that was not conducted with due diligence, are sponsors poking the skunk of a new prohibited act under the FDCA? • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Marketing & Advertising

More from Compliance